Quantifying the Value of the Molecular Tumor Board: Discordance Recommendation Rate and Drug Cost Avoidance.
Mary K WaltersAndrew T AckermanJames L WeeseAntony RuggeriMichael P MullaneAlicia HuntAmanda WilsonBrenda L RamczykMichael A ThompsonPublished in: JCO precision oncology (2022)
Therapeutic recommendation discordance rates can provide quantitative insight into the benefit of MTB. Discordance-associated drug cost avoidance further demonstrates MTB's financial value. These measures may be used as part of the justification for this service line within a cancer care program.